Newest studies

Integrative single-nucleus multi-omics profiling identifies candidate regulators and signaling axes in Alzheimer’s disease lipid-processing microglia

16/100 ⚠ Preprint — not yet peer-reviewed Drug development bioRxiv

Key finding: Lipid-processing microglia are among the microglial states most strongly associated with Alzheimer’s disease (AD) pathology, yet whether this association reproduces across independent cohorts, what transcriptional programs define the state, and which upstream signals and small molecules can modulate it remain unsolved. +2 more findings

• Brain Biology

Scored 32 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

Full summary, score breakdown and related studies → Original source

Using CA1 rather than the whole hippocampus to capture tau-PET Braak stage II

45/100 ✓ Peer-reviewed Brain scans and imaging European Journal of Nuclear Medicine and Molecular Imaging

Key finding: Spatial analyses localised early hippocampal tau-PET signal predominantly to the anterior CA1. +4 more findings

• Brain Scans

Full summary, score breakdown and related studies → Original source

A health ecological model study of subjective cognitive decline among hypertensive patients in rural Shanxi, China

42/100 ✓ Peer-reviewed Risk factors Scientific Reports

Key finding: This study aimed to test the hypothesis that multi-level factors across the five Health Ecological Model (HEM) layers are independently associated with SCD among hypertensive patients in rural China, and to identify specific associated factors within each layer. +4 more findings

• Health Equity
• Lifestyle

Full summary, score breakdown and related studies → Original source

Orexin, Sleep, and Cognition in Alzheimer Disease: Non-REM Oscillatory Activity and Neural Resilience

52/100 ✓ Peer-reviewed Tau biomarkers Neurology

Key finding: Sleep spindles (SPs) and slow oscillations (SOs) are linked to cognition and neurodegeneration; however, their relationship with CSF orexin concentrations in symptomatic AD has not been characterized. +3 more findings

• Biomarkers
• Lifestyle

Full summary, score breakdown and related studies → Original source

Differential association of step count with depressive and anxiety symptoms in older adults at risk of dementia

16/100 ⚠ Preprint — not yet peer-reviewed Clinical trials medRxiv

Key finding: This provides the first evidence in older adults with cognitive concerns that higher step counts are associated with fewer depressive but more anxiety symptoms. +4 more findings

• Risk Factors
• Clinical Trials
• Early Stage

Scored 58 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

Full summary, score breakdown and related studies → Original source

EcoXAI: Autonomous Agentic Ecosystem for Explainable Artificial Intelligence and Biomedical Discovery

16/100 ⚠ Preprint — not yet peer-reviewed Drug development bioRxiv

Key finding: EcoXAI replaces monolithic AI text interfaces with an autonomous execution-driven framework with specialized bioinformatics agents for delivering proactive, data-driven insights grounded in established biological knowledge. +1 more finding

• Digital Tools

Scored 27 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

Full summary, score breakdown and related studies → Original source

Biomarker Variability Limits Individualized Amyloid Time Estimation in Alzheimer Disease

16/100 ⚠ Preprint — not yet peer-reviewed Brain scans and imaging bioRxiv

Key finding: DPM is fundamentally constrained by dynamic range, variability, and test–retest reliability of the biomarker of interest. +1 more finding

• Biomarkers
• Brain Scans

Scored 24 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

Full summary, score breakdown and related studies → Original source

En respuesta a «Avances y controversias de los tratamientos de la enfermedad de Alzheimer»

29/100 ✓ Peer-reviewed Treatments Atención Primaria

Key finding: controversias de los tratamientos de la enfermedad de Alzheimer» In response to 'Advances and controversies in the treatments of Alzheimer's disease' Sr. +1 more finding

• Treatments

Full summary, score breakdown and related studies → Original source

Perspectives and Insights on Anti-Amyloid Immunotherapy Agents: From Development to Submission of a New Drug Submission (NDS) in Canada

41/100 ✓ Peer-reviewed Treatments Zenodo (CERN European Organization for Nuclear Research)

Key finding: Anti-amyloid immunotherapy agents represent a novel and clinically significant class of humanized monoclonal antibodies designed to selectively bind and clear pathological amyloid-beta (Aβ) aggregates from the brain, thereby slowing the progression of early Alzheimer’s disease (AD).

• Treatments
• Side Effects

Full summary, score breakdown and related studies → Original source

Perspectives and Insights on Anti-Amyloid Immunotherapy Agents: From Development to Submission of a New Drug Submission (NDS) in Canada

28/100 ✓ Peer-reviewed Treatments Zenodo (CERN European Organization for Nuclear Research)

Key finding: Anti-amyloid immunotherapy agents represent a novel and clinically significant class of humanized monoclonal antibodies designed to selectively bind and clear pathological amyloid-beta (Aβ) aggregates from the brain, thereby slowing the progression of early Alzheimer’s disease (AD).

• Treatments
• Side Effects

Full summary, score breakdown and related studies → Original source

Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease: An Individual Participant Data Meta-Analysis

52/100 ✓ Peer-reviewed Biomarkers Apollo (University of Cambridge)

Key finding: This meta-analysis included cross-sectional amyloid PET scans acquired with 5 radiotracers from 49 227 participants across 53 studies from 15 countries (mean age, 71 years; 54% female, 62% cognitively impaired). +4 more findings

• Brain Scans

Full summary, score breakdown and related studies → Original source

Performance of Alzheimer Disease Plasma Biomarkers in Patients With Prion Diseases

64/100 ✓ Peer-reviewed Tau biomarkers Neurology

Key finding: Prion diseases can mimic Alzheimer disease (AD) at presentation. +3 more findings

• Biomarkers

Full summary, score breakdown and related studies → Original source

Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease: An Individual Participant Data Meta-Analysis

79/100 ✓ Peer-reviewed Getting a diagnosis JAMA

Key finding: The double-cutoff approach revealed high confidence for interpreting scans as negative when Centiloid values were lower than 11 (95% CI, 9-13; I2 = 95%) and interpreting scans as positive if Centiloid values were higher than 26 (95% CI, 24-28; I2 = 95%). +2 more findings

• Diagnosis
• Brain Scans

Full summary, score breakdown and related studies → Original source

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial

72/100 ✓ Peer-reviewed Prevention and risk The Lancet

Key finding: These findings extend the evidence base for multidomain lifestyle interventions to populations historically under-represented in dementia research, supporting their feasibility and scalability as strategies to reduce cognitive decline risk amid the rapidly growing burden of dementia in low-income and middle-income countries. +2 more findings

• Clinical Trials
• Prevention
• Lifestyle

Full summary, score breakdown and related studies → Original source

Clinicopathologic Evaluation of Amyloid Clearance in Alzheimer Disease

54/100 ✓ Peer-reviewed Drug development JAMA

Key finding: The long-term efficacy of amyloid-targeting therapies hinges on their ability to slow downstream neuropathologic change, but little is known about the influence of amyloid clearance on tau pathology and neurodegeneration. +3 more findings

• Treatments
• Clinical Trials
• Brain Biology

Full summary, score breakdown and related studies → Original source

Comparing Harmonization Approaches for Protocol-Related Variability in Multisite Diffusion MRI Data

16/100 ⚠ Preprint — not yet peer-reviewed Brain scans and imaging bioRxiv

Key finding: Overall, multiple strategies effectively modeled protocol-related variability while preserving AD-related associations.

• Brain Scans

Scored 21 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

Full summary, score breakdown and related studies → Original source

CSF and plasma tau biomarkers in the Down syndrome-Alzheimer's disease continuum

66/100 ✓ Peer-reviewed Biomarkers EBioMedicine

Key finding: We analysed 461 participants from the DABNI and SPIN cohorts. +4 more findings

• Biomarkers

Full summary, score breakdown and related studies → Original source

Comparison of a multi-analyte algorithmic immunoassay blood test with immunoprecipitation mass spectrometry for the detection of amyloid pathology

46/100 ✓ Peer-reviewed Health systems and care delivery Alzheimer's & dementia (Amsterdam, Netherlands)

Key finding: Symptomatic individuals (n = 192) with longitudinal samples from Alzheimer's Disease Neuroimaging Initiative (ADNI) were analyzed versus amyloid positron emission tomography (PET). +3 more findings

• Biomarkers

Full summary, score breakdown and related studies → Original source

Alzheimer Disease Biomarkers and Subjective Cognitive Decline Among Hispanic and/or Latino Adults

45/100 ✓ Peer-reviewed Genetics UNC Libraries

Key finding: Among 5712 adults (mean [SD] age, 63.47 (8.15) years; unweighted 3663 [53.92%] female), higher ln(ptau-181) was associated with ECog-12 memory (unstandardized β = 0.088; 95% CI, 0.005-0.170). +4 more findings

• Health Equity
• Biomarkers

Full summary, score breakdown and related studies → Original source

Biomarker-informed CSF proteomics reveals ENPP2–LPA lipid signaling associated with Alzheimer’s disease

16/100 ⚠ Preprint — not yet peer-reviewed Disparities medRxiv

Key finding: We validated results in CSF from 397 participants in the Accelerated Medicine Partnership-Alzheimer’s Disease cohort. +4 more findings

• Biomarkers

Scored 35 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

Full summary, score breakdown and related studies → Original source

Longitudinal plasma proteomics separates diagnostic differences from progression-linked changes in Alzheimer’s disease

16/100 ⚠ Preprint — not yet peer-reviewed Prevention trials medRxiv

Key finding: Thirteen proteins were supported in two or more domains and six in three. +4 more findings

• Diagnosis

Scored 47 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

Full summary, score breakdown and related studies → Original source

Primary Care Cost Sharing in Medicare Advantage

50/100 ✓ Peer-reviewed Health systems and care delivery JAMA Health Forum

Key finding: Secondary outcomes included plan- and county-level factors associated with offering this benefit in 2025, estimated using multivariable mixed-effects logistic regression with county-level random intercepts. +1 more finding

• Policy
• Care Services

Full summary, score breakdown and related studies → Original source

Estimates of Incidence and Prevalence of Conversions to Mild Cognitive Impairment and Dementia in Patients With Essential Tremor

58/100 ✓ Peer-reviewed How common it is Neurology

Key finding: Cumulative prevalences of MCI and dementia were 22.0% (95% confidence interval [CI] = 18.0-26.6) and 14.6% (95% CI = 11.3-18.7), cumulative incidences were 12.9% (95% CI = 9.3-17.6) and 10.2% (95% CI = 7.2-14.2), respectively, and the average annual proportion of conversions from MCI to dementia was 13.8%. +4 more findings

• Early Stage

Full summary, score breakdown and related studies → Original source

Early Prediction of Parkinson’s Disease Progression by Integrating Research Cohort and Real-World Data Using Knowledge-Anchored Graph Learning

16/100 ⚠ Preprint — not yet peer-reviewed Digital health tools medRxiv

Key finding: Graph-based model interpretation revealed clinical and molecular drivers involving cognitive vulnerability, α-synuclein biology, vesicle trafficking and neuroinflammation. +1 more finding

• Other Dementias

Scored 35 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

Full summary, score breakdown and related studies → Original source

Seven routine blood markers predict five-year mortality in older Indians: a risk score from the LASI-DAD cohort

16/100 ⚠ Preprint — not yet peer-reviewed End-of-life care Research Square

Key finding: Among 2144 participants (540 deaths over a median 4.4 years of survivor follow-up; 25% mortality), the seven-marker score plus age and sex achieved an apparent C of 0.74 (optimism-corrected 0.74), versus 0.68 for age and sex alone (Δ ≈ 0.06); the blood panel alone reached C 0.72. +1 more finding

Scored 45 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

Full summary, score breakdown and related studies → Original source